Merck (NYSE: MRK) has performed poorly in the stock market this year, with the drugmaker's shares down by 5%. But zooming out helps put a different spin on this story as the pharmaceutical giant has easily crushed the broad equity indexes over the past 12 months.
Perhaps Merck is dealing with temporary headwinds and will return to its market-beating ways soon. Or is the company facing severe problems that will continue to harm its stock price? Let's find out whether it's worth buying shares of Merck today.
Source Fool.com